Northern Illinois University

Huskie Commons
Honors Capstones

Undergraduate Research & Artistry

4-24-2017

The Synthesis of Carborane-Appended Dopamine and L-Dopa for
Boron Neutron Capture Therapy
L. Zuidema

Follow this and additional works at: https://huskiecommons.lib.niu.edu/studentengagementhonorscapstones

Recommended Citation
Zuidema, L., "The Synthesis of Carborane-Appended Dopamine and L-Dopa for Boron Neutron Capture
Therapy" (2017). Honors Capstones. 1295.
https://huskiecommons.lib.niu.edu/studentengagement-honorscapstones/1295

This Dissertation/Thesis is brought to you for free and open access by the Undergraduate Research & Artistry at
Huskie Commons. It has been accepted for inclusion in Honors Capstones by an authorized administrator of
Huskie Commons. For more information, please contact jschumacher@niu.edu.

NORTHERN ILLINOIS UNIVERSITY
The Synthesis of Carborane-Appended Dopamine and L-Dopa for Boron Neutron
Capture Therapy
A Thesis Submitted to the
University Honors Program
In Partial Fulfillment of the
Requirements of the Baccalaureate Degree
With Upper Division Honors
Department of Chemistry and Biochemistry
By
Lauren Zuidema
DeKalb, Illinois
Spring 2017

Abstract
With a series of reactions, biological molecules Dopamine and L-Dopa were conjugated with
carborane in an effort to synthesize new boron delivery agents for a bimodal cancer treatment
known as Boron Neutron Capture Therapy (BNCT). The products of these reactions were
purified using column chromatography, and characterized with Fourier-Transform Infrared
Spectroscopy (FT-IR) and Nuclear Magnetic Resonance (NMR) Spectroscopy. The successful
synthesis of carborane-appended dopamine and L-Dopa has been supported with
characterizations performed thus far. In the future, the compounds will undergo further analysis
with elemental analysis, mass spectroscopy, and biodistribution studies to determine cytotoxicity
and cellular uptake in the future.

Introduction
Boron Neutron Capture Therapy (BNCT) is a bimodal cancer treatment which is based on
the selective accumulation of Boron-10 (10B) atoms into cancer cells using biologically compatible
boron delivery agents.1 10B can be irradiated with a beam of low-energy neutrons to produce 11B
atoms. These atoms break down into Helium-4 (4He) alpha particles and Lithium-7 (7Li) atoms,
and produce 2.4 MeV of energy.1 The high linear energy transfer (LET) alpha particles and 7Li
particles travel approximately 5-9 µm, which is the dimeter of one cell.1,2 The distance traveled by
these particles results in the destruction of only the cells containing a sufficient amount of
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atoms (Figure 1).1,2 As cancer cells are selectively destroyed, the surrounding healthy cells are not
affected.3 This greatly reduces the side effects associated with traditional cancer treatment methods
such as chemotherapy and radiation. With the use of BNCT, patients will experience a better
quality of life during their treatment.3 Therefore, selective accumulation of boron containing
compounds into cancerous cells only is very desirable, and has become the focus of current
research with BNCT.3

Figure 1: BNCT Mechanism
Currently, there are only two boron delivery agents that have been approved by the FDA
for clinical use. These compounds include boronophenylalanine fructose (BPA) and sodium

borocaptate (BSH) (Figure 2).1 BPA is a derivative of amino acid tyrosine, and has been used to
treat skin cancers, whereas BSH is a boron cluster which has been used to treat brain tumors.1
Although successful, these compounds have limitations. BSH contains a sulfur atom, which can
bond to other sulfur atoms to form disulfide bridges. This causes the formation of dangerous
radicals in the body, and can cause negative side effects. BPA has only one Boron atom per
molecule, and therefore requires high dosages for substantial boron accumulation into the cells. In
order to successfully destroy a cancer cell, the boron content of that cell must be between 20-35
µg/g of tumor tissue, but a low concentration of 10B must be maintained in surrounding healthy
cells.1,2 Therefore, current research has been focused on the synthesis of new boron delivery agents
that have a high concentration of boron atoms and are biologically compatible.

(a)

(b)
Figure 2: (a) BSH (b) BPA

Carborane is a biologically compatible molecule with a cage structure that contains ten
boron atoms. Because of its properties, carborane would be an excellent boron carrier, and would
allow faster accumulation of the necessary amount of boron in cancer cells. However, carborane
cannot be taken up by cells on its own. Cancer cells take up large amounts of nutrients such as
glucose, amino acids, and neurotransmitters to facilitate their rapid growth, but would not take up
an individual carborane molecule. Therefore, by conjugating carborane with a molecule that would

normally be taken up by cancer cells, the carborane cage can be disguised using the “Trojan Horse
Method” and will be able to enter the cell. Although all cells will take up the carborane appended
biomolecule, cancer cells will take up much larger amounts. Healthy cells will then metabolize the
small amount of boronated compound, and it will safely exit the body. As cancerous cells will
have a higher concentration of the boronated compound, some will still remain after it has been
removed from the healthy cells. It is at that time that the neutron beam will irradiate the cancerous
cells, and the reaction to destroy only those cells will occur.
To successfully disguise the carborane cage and facilitate uptake by cancerous cells,
carborane will be conjugated with Dopamine and L-Dopa. Dopamine is a neurotransmitter that
plays a role in several functions such as movement, memory, the reward system, sleep, and mood,
and is found in many locations throughout the body.4 L-Dopa is a precursor of Dopamine, and,
unlike dopamine, can cross the blood-brain-barrier (BBB).4 To treat brain tumors, the boron carrier
must be able to pass through the BBB, which is very selective. It is freely permeable to water, and
is able to uptake molecules such as glucose, L-Dopa, and amino acids through selective
transporters.5 Generally, the solubility of a compound in lipids positively correlates with the ability
of a compound to pass through the blood brain barrier. Water and ethanol have high lipid solubility
and can pass freely through the BBB, while L-Dopa and glucose have lower lipid solubility and
require specific carriers to facilitate their passage (Figure 3).5 Although L-Dopa enters the brain
quickly, enzymes called L-Dopa decarboxylase and monoamine oxidase break down L-Dopa and
limit the amount that is able to enter the central nervous system.5 Because of this, large doses of
the synthesized carborane-appended L-Dopa would be needed for effective BNCT treatment.
However, a drug called carbidopa reduces decarboxylation of L-Dopa, and could be administered
with L-Dopa to increase uptake.5

Figure 3: Uptake of various compounds through the BBB.5
As the structures of both Dopamine and L-Dopa are very similar to that of BPA, the
conjugation of Dopamine and L-Dopa with carborane could be viable options for the synthesis of
boron delivery agents for BNCT.6 The synthesis of these new boron delivery agents would
decrease side effects, as there would be no possibility of the formation of disulfide bridges, and
would allow for high concentrations of boron to be taken up by the cells.6 Through the continuation
of research, BNCT will improve and will become a safe and widely used method of treatment for
many types of cancers.

Materials and Methods
Each reaction done in this research project has included the use of various laboratory
equipment such as round bottom flasks, magnetic stir bar and hot plate, TLC paper, silica-gel
column, ultraviolet lamp, rotary evaporator, and distilling apparatus including heating tape. The
reactions were performed under argon or nitrogen gas using Schlenk lines to ensure an inert
environment and ideal reaction conditions. The chemicals involved in these reactions were used

without further purification and include previously prepared and purified 1-iodobutyl-o-carborane,
dopamine HCl, L-Dopa, sodium hydroxide, hexane, hydrochloric acid, methanol, and
dimethylformamide. The method by which 1-iodobutyl-o-caarborane was prepared can be seen in
Scheme 1.

Scheme 1: Synthesis of 1-iodopropyl-o-carborane
1. Synthesis of Carborane Appended Dopamine

Scheme 2: Synthesis of carborane-appended dopamine using dimethylformamide.

Sodium hydroxide (160.3 mg, 4.00 mmol) was added to 100 mL DMF in an oven-dried
250 mL round-bottom flask, and was sonicated for 30 minutes. After the sodium hydroxide had
dissolved, dopamine hydrochloride (39.8 mg, 0.210 mmol) and 1-iodopropyl-o-carborane (129.7
mg, 0.422 mmol) were added to the flask. The mixture was refluxed for 48 hours at 80oC.
Following the reflux, the dimethylformamide solvent was removed in small fractions using
distillation, leaving the crude product. This crude product was then purified using silica gel column
chromatography (SiO2, eluted with hexane and dimethylformamide) and TLC (SiO2, developed
with hexane, dimethylformamide). The solvent was then again removed from the purified product
using distillation, and the product was dried under vacuum for 10 hours. The product was then
characterized using Fourier-Transform Infrared Spectroscopy shown in Figure 4, and 1H, 11B, and
13

C NMR in dimethyl sulfoxide (DMSO) solvent shown in Figures 2, 3, and 4. In an effort to

remove some of the excess salt that was formed during the reaction, a small portion of the product
was washed with water. The washed product as well as the unwashed product were taken for
characterization using elemental analysis, and the results were compared with the elemental
analysis of unreacted dopamine hydrochloride (Table 1).

2. Synthesis of Carborane Appended L-Dopa
a. Protection of Carboxylic Acid using Fischer Esterification
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Scheme 3: Fischer Esterification reaction

Reaction I:
First, 15 mL of methanol was added to a 50 mL round bottom flask. 49.8 mg of L-Dopa
was measured using a laboratory balance and then was added to the flask. This was cooled with
ice for five minutes before 1 mL concentrated HCl was added dropwise into the solution with
continued cooling and stirring. The mixture was then allowed to return to room temperature before
beginning reflux at 50oC. The reflux was continued overnight, and then the solvent was removed
with rotary evaporation. The sticky yellow product was analyzed with Fourier Transform Infrared
Spectroscopy, 1H NMR, and 13C NMR as seen in Figures 5, 6, and 7, respectively. Following this
initial analysis, the product was dried further under vacuum conditions to produce an off-white,
fluffy solid. This product was again analyzed using 1H NMR,

13

C NMR, and FTIR as seen in

Figures 8, 9, and 10, respectively.

Reaction II:
In order to produce a more substantial amount of product for use in the reaction depicted
in Scheme 3, a larger scale reaction was completed. 60 mL methanol was added to a 250 mL round
bottom flask. Then, 200.7 mg L-Dopa was added to the flask with a magnetic stir bar. This mixture
was placed on ice to cool and stir for approximately five minutes before the addition of 4.2 mL
concentrated HCl in a dropwise manner. The clear solution was allowed to stir on ice for
approximately five minutes before being allowed to return to room temperature while stirring. The
solution was then heated to 50oC to reflux overnight. The following day, the solvent was removed
with rotary evaporation to produce a sticky yellow product as observed in Reaction I. This product
was then dried under vacuum conditions overnight to produce an off-white, fluffy solid.

b. Addition of Carborane Cage

Scheme 4: Synthesis of carborane-appended L-Dopa
To finish the synthesis of carborane appended L-Dopa, the second part of the procedure
was performed as follows. Sodium hydroxide (42.4 mg, 1.00 mmol) was added to 50 mL DMF
in an oven-dried 250 mL round-bottom flask and was sonicated for 30 minutes. 50 mL DMF was
also added to the flask containing the protected L-Dopa (281.4 mg, 1.33 mmol). Following the
dissolution of the sodium hydroxide, the solution containing the protected L-Dopa and was
added to the sodium hydroxide and DMF solution. Then, 1-iodopropyl-o-carborane (312.7 mg,
1.01 mmol) was added to the flask. The solution was refluxed for 16 hours at 80oC before the
solvent was removed through distillation. The product obtained from this reaction was then
characterized using FTIR and 1H, 13C, and 11B NMR (Figures 11, 12, 13, and 14).

Results
1. Synthesis of Carborane Appended Dopamine

Figure 4: FTIR spectra of unreacted dopamine HCl (red) compared with purified carborane
appended dopamine (blue).

Figure 5: 1H NMR of purified carborane-appended dopamine.

Figure 6: 13C NMR of purified carborane-appended dopamine.

Figure 7: 11B NMR of purified carborane-appended dopamine

Sample
Dopamine Hydrochloride

Carborane-Appended Dopamine
(Before wash with DI water)
Carborane-Appended Dopamine
(After wash with DI water)

Expected
C: 50.67%
H: 6.38%
N: 7.39%
C: 43.10%
H: 4.62%
N: 2.79%
C: 43.10%
H: 4.62%
N: 2.79%

Observed
C: 50.77%
H: 6.36%
N: 8.64%
C: 39.88%
H: 8.75%
N: 12.05%
C: 49.37%
H: 9.85%
N: 3.09%

Table 1: Elemental Analysis results for procedure outlined in Scheme 2.

2. Synthesis of Carborane Appended L-Dopa
a. Protection of Carboxylic Acid using Fischer Esterification

Figure 8: Fourier Transform Infrared Spectroscopy of L-Dopa (Red) and L-Dopa with a methyl
group protecting the carboxylic acid ((Blue) (Reaction I)) before drying.

Figure 9: 1H NMR of protected L-Dopa before drying (Reaction I).

Figure 10: 13C NMR of protected L-Dopa before drying (Reaction I)

Figure 11: 1H NMR of protected L-Dopa following dying under vacuum conditions (Reaction 1).

Figure 12: 13C NMR of protected L-Dopa following drying under vacuum conditions (Reaction
I).

Figure 13: FTIR of protected L-Dopa following drying under vacuum conditions (Reaction I).
b. Addition of Carborane Cage

Figure 14: FTIR of L-Dopa (red), methyl protected L-Dopa (dark blue), and carboraneappended L-Dopa (bright blue).

Figure 15: 1H NMR of carborane-appended L-Dopa.

Figure 16: 13C NMR of carborane-appended L-Dopa

Figure 17: 11B NMR of carborane-appended L-Dopa
Discussion
1. Synthesis of Carborane Appended Dopamine
When the product obtained as described in Scheme 2 was purified and the solvent was
removed with distillation, it was dark brown in color and very waxy. Initially, it was
hypothesized that there could be a small amount of DMF left in the product. After many hours of
drying under vacuum, a brown clumpy solid was formed. In Figure 4, the FTIR spectra of
dopamine hydrochloride and the purified carborane appended dopamine product are compared.
The large peak at 3400 to 3000 cm-1 which represent the OH groups on the dopamine
hydrochloride shifted to the left and centered at 3500 cm-1. This indicates that the OH groups
were removed, and the peak at 3500 cm-1 is representative of the NH2 group in the carborane
appended dopamine. Additionally, a strong peak appeared at 2500 cm-1 in the spectrum of the

product, which is indicative of a B-H bond. This suggests that the carborane cage was
successfully attached to the dopamine.
The 11B NMR shown in Figure 7 further supports this conclusion, as there are ten peaks in
the spectrum, which correspond to the ten boron atoms in a carborane cage. The 1H NMR and
13

C NMR seen in Figures 5 and 6, respectively, are not as promising, as there are not as many

signals as expected. Additionally, the results from elemental analysis can be seen in Table 1. The
values obtained from the analysis of the carborane-appended dopamine product are slightly
different from the expected values, but do not give reason to believe that the synthesis of the
compound was unsuccessful. One of the most significant differences was in the nitrogen content
of the carborane-appended dopamine before being washed with water. Rather than the expected
2.79%, the nitrogen content was 12.05%. Additionally, before being washed with water, the
carborane-appended dopamine exhibited a carbon content of 39.88%. After being washed with
water, the carbon content increased to 49.37% as compared to the 43.10% that is expected. These
discrepancies, although larger than would be normally accepted, can be attributed to the
calibration curve that was produced by the elemental analysis apparatus. The calibration curve
was significantly deviant from the normal range, and contributed to the value differences
between expected and observed. Because of this, the results from elemental analysis are
inconclusive. This method of characterization will therefore be performed again to obtain more
credible results.
2. Synthesis of Carborane Appended L-Dopa
a. Protection of Carboxylic acid with Fischer Esterification
After completion of the reaction outlined in Scheme 3 aimed to protect the carboxylic acid
group with a methyl group, a sticky, yellow product was obtained. The product was characterized

using FTIR and compared with the FTIR of the starting material L-Dopa, as seen in Figure 8.
There are some differences in the spectra indicating that a favorable reaction did occur. Because
the desired product has only one additional carbon that has replaced a hydroxyl group on the
carboxylic acid, it is difficult to determine the success of the reaction solely from the FTIR Spectra.
However, the desired peaks are present. In the spectrum of the product following drying under
vacuum condition (Figure 13), a stretch at 1735 cm-1 indicates a carbonyl carbon, while stretches
at 1287 cm-1and 1117 cm-1 indicate a C-O bond. Additionally, the large stretch at 3214 cm-1
indicates the OH groups and NH3 groups that are still present on the L-Dopa.
In the 13C NMR spectra in Figure 12, the peaks at 110-120 ppm indicate a C-O bond. Likewise,
the peak at approximately 3.8 ppm indicates the presence of an RO-CH3 bond in the 1H NMR
spectra (Figure 11). Additionally, in the 1H NMR (Figure 11), the peak at 10-13 ppm that would
represent a carboxylic acid is not present. All of these peaks indicate that the reaction was
successful in protecting the carboxylic acid with a methyl group.
b. Addition of Carborane Cage
From the characterizations obtained on the product from the reaction outlined in Scheme 3, it is
promising that the desired compound, carborane-appended L-Dopa, was synthesized. In Figure 14,
there is a characteristic peak at approximately 2600 cm-1 indicating the presence of B-H bonds.
Additionally, the peak at approximately 3500 cm-1 is sharp, which means that there is an amine in
the compound. The absence of the broad –OH peak at this location indicates that the carborane
cages were attached to the –OH groups on the L-Dopa. The 11B NMR spectrum in Figure 17 shows
10 peaks for the 10 boron atoms in a carborane cage. Additionally, the 13C NMR in Figure 16 has
a peak at approximately 220 ppm indicating a carbonyl bond. The small peaks at approximately

125 ppm indicate aromatic carbons, which are found in the ring. These peaks are all positive
indications of the successful synthesis of carborane-appended L-Dopa.

Conclusion
As the synthesis of these molecules has been determined to be successful thus far, it will
be necessary to continue research on this subject in order to fully characterize the compounds and
determine their biological compatibility. Mass spectrometry and additional trials in elemental
analysis will further solidfy the identities of the compounds, and biodistribution studies will be
conducted to determine each compound’s cytotoxicity and cellular uptake in cancer cell lines. With
positive results in these areas, clinical trials would follow. With the successful synthesis of these
boron delivery agents, Boron Neutron Capture Therapy will continue to make advancements, and
the use of BNCT as a cancer treatment will become more widespread. Patients will benefit from
advancements in this area by experiencing fewer side effects than with traditional cancer therapies,
and fewer treatments overall.7 In addition to this avenue of research, future directions could include
increasing tumor cell specificity and tissue selectivity for even more reduced side effects on
healthy cells, exploring the development of neutron beams specifically for BNCT to improve
treatment success, and investigating treatment planning including specific drug doses and timing
of treatment for patients on an individual basis.8,9 Although there is much research to be done in
this field, BNCT is a promising method of cancer therapy that will greatly benefit patients suffering
from many different types of cancers.
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